ACLU Challenges Patents on Breast Cancer Genes

Publication
Article
OncologyONCOLOGY Vol 23 No 7
Volume 23
Issue 7

The American Civil Liberties Union and the Public Patent Foundation at Benjamin N. Cardozo School of Law filed a lawsuit charging that patents on two human genes associated with breast and ovarian cancer stifle research that could lead to cures and limit women’s options regarding their medical care.

The American Civil Liberties Union and the Public Patent Foundation at Benjamin N. Cardozo School of Law filed a lawsuit charging that patents on two human genes associated with breast and ovarian cancer stifle research that could lead to cures and limit women's options regarding their medical care. Mutations along the BRCA1 and BRCA2 genes are responsible for most cases of hereditary breast and ovarian cancers. The lawsuit argues that the patents on these genes are unconstitutional and invalid.

Articles in this issue
What Is the Optimal Initial Treatment of Low-Risk Papillary Thyroid Cancer (and Why Is It Controversial)?
What Is the Optimal Initial Treatment of Low-Risk Papillary Thyroid Cancer (and Why Is It Controversial)?
Low-Risk Papillary Thyroid Cancer: Treatment Options and Patient Perceptions
Can Risk-Adapted Treatment Recommendations Replace the ‘One Size Fits All’ Approach for Early-Stage Thyroid Cancer Patients?
Prophylactic Central Lymph Node Dissection: Continued Controversy
Music Therapy
Music Therapy
LHRH Antagonists vs LHRH Agonists: Which Is More Beneficial in Prostate Cancer Therapy?
Is There a Role for LHRH Antagonists in Prostate Cancer?
Important Considerations in LHRH Antagonist Therapy for Prostate Cancer
The Role of LHRH Antagonists in the Treatment of Prostate Cancer
Maintenance Therapy With Pemetrexed Improves Overall Survival in Advanced NSCLC
PARP Inhibitors Show Promise for Hard-to-Treat Breast Cancers
Therapeutic Cancer Vaccine Significantly Prolongs Disease-Free Survival for Follicular Lymphoma
Vaccine Improves Response Rate and Extends Progression-Free Survival in Metastatic Melanoma
‘Natural’ Hormone Replacement and Breast Cancer Risk: Evidence for Safety and Efficacy
Phase IIIB Trial of Intermittent Degarelix Therapy Launched
Recent Videos
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Related Content
28 Enhancing the Interpretation of Real-World Quality of Life (QoL) in Patients With Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2-) Advanced Breast Cancer (ABC) Enrolled in the POLARIS Trial

28 Enhancing the Interpretation of Real-World Quality of Life (QoL) in Patients With Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2-) Advanced Breast Cancer (ABC) Enrolled in the POLARIS Trial

Gabrielle Rocque;Joanne L. Blum, MD, PhD;Yan Ji;Eric Gauthier;Yao Wang;Monica Z. Montelongo;Joseph C. Cappelleri;Connie Chen;Meghan S. Karuturi;Debu Tripathy, MD
July 24th 2024
Article
Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Applying Updated Breast Cancer Findings From ASCO to Clinical Practice

Neil M. Iyengar, MD;Paolo Tarantino, MD
June 17th 2024
Podcast

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

29 ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Patients (pts) With Estrogen Receptor–Positive (ER+), HER2-Negative (HER2–) Locally Advanced or Metastatic Breast Cancer (mBC)

29 ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Patients (pts) With Estrogen Receptor–Positive (ER+), HER2-Negative (HER2–) Locally Advanced or Metastatic Breast Cancer (mBC)

Hope S. Rugo, MD;Aditya Bardia, MD, MPH;Erika P. Hamilton, MD;Sara A. Hurvitz, MD;Sara M. Tolaney, MD, MPH;Virginia Kaklamani, MD, DSc;Paula Muñoz Romero;Shannon Matheny;Kathy Puyana Theall;Joyce A. O’Shaughnessy
July 21st 2024
Article
Neil M. Iyengar, MD, spoke about the potential impact of exercise on patient-reported outcomes in cancer and achieving work-life balance.

Finding a Place for Exercise Oncology in the Treatment of Breast Cancer

Neil M. Iyengar, MD
May 20th 2024
Podcast

Neil M. Iyengar, MD, spoke about the potential impact of exercise on patient-reported outcomes in cancer and achieving work-life balance.

Two dose-limiting toxicities were observed, and the maximum tolerated dose was not reached in a study evaluating FS-1502 safety, tolerability, and efficacy.

FS-1502 Demonstrates Promising Antitumor Activity in HER2+ Breast Cancer

Roman Fabbricatore
July 19th 2024
Article

Two dose-limiting toxicities were observed, and the maximum tolerated dose was not reached in a study evaluating FS-1502 safety, tolerability, and efficacy.

Assessing Dermatologic Responses to Amivantamab in EGFR-Mutated NSCLC

Assessing Dermatologic Responses to Amivantamab in EGFR-Mutated NSCLC

ONCOLOGY Staff
July 17th 2024
Article

The conundrum of treating dermatologic adverse effects in response to treatment with amivantamab for EGFR-mutated NSCLC was discussed in a recent Frontline Forum.